BSE filing, NSE: PML. Summary written from the filing by ALFA Finder's alert engine.
Paul Merchants Ltd: key numbers
- Share price
- ₹493.35
- Market cap
- ₹152.2 Cr
- Revenue (annual)
- ₹2,074 Cr
- Net profit (annual)
- ₹268.7 Cr
- P/E (TTM)
- -15.5×Sector 19.7×
- Promoter holding
- 74.65%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Paul Merchants Ltd
All →Paul Merchants Credit Rating
Infomerics assigned IVR BBB+/Stable to facilities of wholly owned subsidiary Paul Merchants Finance. No downward revision was reported, making this a routine rating action.
Paul Merchants Other Announcement
Paul Merchants Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Paul Merchants Legal & Regulatory
Paul Merchants received two RBI orders imposing a total penalty of Rs. 20,000 for regulatory contraventions at its Cochin and Tanda branches.
- Value
- ₹0.00 Cr
Paul Merchants Management Change
Paul Merchants shareholders approved the re-appointment of Mr. Ritesh Vaid as Designated Whole Time Director for five years effective October 1, 2026.
- Execution
- 5 years
Paul Merchants Annual General Meeting
Paul Merchants Ltd conducted its 42nd Annual General Meeting on September 18, 2026. The meeting discussed financial statements and director reappointment resolutions.
Paul Merchants Other Announcement
Paul Merchants issued a communication to shareholders as per Regulation 36(1)(b) requesting email registration for electronic receipt of future corporate notices and the 42nd AGM.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.